The high HIV-1 viral diversity is a formidable hurdle for the development of an HIV-1 vaccine. Elicitation of broadly neutralizing antibodies (bNAbs) would offer a solution, but so far immunization strategies have failed to elicit bNAbs efficiently. To overcome the obstacles, it is important to understand the immune responses elicited by current HIV-1 envelope glycoprotein (Env) immunogens. To gain more insight, we characterized monoclonal antibodies (mAbs) isolated from rabbits immunized with Env SOSIP trimers based on the clade B isolate AMC008. Four rabbits that were immunized three times with AMC008 trimer developed robust autologous and sporadic low-titer heterologous neutralizing responses. Seventeen AMC008 trimer-reactive mAbs were i...
Abstract An effective HIV-1 vaccine probably will need to be able to induce broadly neutralizing HIV...
A small proportion of HIV-infected individuals generate a neutralizing antibody (NAb) response of ex...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
AbstractThe elicitation of broadly neutralizing antibodies directed against the human immunodeficien...
Abstract An effective human immunodeficiency virus type I (HIV-1) vaccine that robustly elicits broa...
The recent isolation of HIV broadly neutralizing antibodies (bNAbs) from HIV infected individuals ha...
After over 35 years of research, a prophylactic HIV vaccine remains elusive. However, the discovery ...
After over 35 years of research, a prophylactic HIV vaccine remains elusive. However, the discovery ...
Abstract Despite enormous efforts no HIV-1 vaccine has been developed that elicits broadly neutraliz...
HIV-1 broadly neutralizing antibodies are desired for their therapeutic potential and as templates f...
Recombinant soluble HIV-1 envelope glycoprotein (Env) SOSIP trimers are a design platform for induci...
Rationally designed protein subunit vaccines are being developed for a variety of viruses including ...
A small proportion of HIV-infected individuals generate a neutralizing antibody (NAb) response of ex...
Abstract An effective HIV-1 vaccine probably will need to be able to induce broadly neutralizing HIV...
A small proportion of HIV-infected individuals generate a neutralizing antibody (NAb) response of ex...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
AbstractThe elicitation of broadly neutralizing antibodies directed against the human immunodeficien...
Abstract An effective human immunodeficiency virus type I (HIV-1) vaccine that robustly elicits broa...
The recent isolation of HIV broadly neutralizing antibodies (bNAbs) from HIV infected individuals ha...
After over 35 years of research, a prophylactic HIV vaccine remains elusive. However, the discovery ...
After over 35 years of research, a prophylactic HIV vaccine remains elusive. However, the discovery ...
Abstract Despite enormous efforts no HIV-1 vaccine has been developed that elicits broadly neutraliz...
HIV-1 broadly neutralizing antibodies are desired for their therapeutic potential and as templates f...
Recombinant soluble HIV-1 envelope glycoprotein (Env) SOSIP trimers are a design platform for induci...
Rationally designed protein subunit vaccines are being developed for a variety of viruses including ...
A small proportion of HIV-infected individuals generate a neutralizing antibody (NAb) response of ex...
Abstract An effective HIV-1 vaccine probably will need to be able to induce broadly neutralizing HIV...
A small proportion of HIV-infected individuals generate a neutralizing antibody (NAb) response of ex...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...